Ozempic® Approved by TGA for Chronic Kidney Disease in Type 2 Diabetes Patients
The Therapeutic Goods Administration (TGA) has approved Ozempic® (semaglutide 1.0 mg) for reducing the risk of kidney disease progression in Australians with type 2 diabetes and chronic kidney disease (CKD). This label expansion marks a significant step in addressing the growing burden of CKD, which affects an estimated 330,000 Australians…